Inflammatory Bowel Disease Increases Risk for Later Arrhythmias
MONDAY, Nov. 6, 2023 -- Patients with inflammatory bowel disease (IBD) overall, as well as Crohn disease (CD) and ulcerative colitis (UC) individually, have an increased risk for developing later arrhythmias, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 6, 2023 Category: Pharmaceuticals Source Type: news
A vitamin K
Whether you snag some vitamin C at the first sign of a cold or stock up on probiotics to keep your gut health in check, you’re not alone in turning to dietary supplements—an estimated 75% of Americans use them. Among the various types, vitamin K is gaining popularity due to its potential benefits…#vitamink #viola #fortune #vitamink3 #oncologyletters #k2 #canola #vitamink2 #vitamink1 #crohn (Source: Reuters: Health)
Source: Reuters: Health - November 4, 2023 Category: Consumer Health News Source Type: news
FDA Approves Subcutaneous Infliximab for IBD FDA Approves Subcutaneous Infliximab for IBD
The approval provides an alternative administration option for delivering the drug to patients with moderately to severely active ulcerative colitis or Crohn ' s disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 23, 2023 Category: Consumer Health News Tags: Gastroenterology News Alert Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
Roche will gain the rights to develop, manufacture and commercialise RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseasesRVT-3101 is a Phase 3-ready antibody with first-in-class and best-in-disease potential, a novel mode of action and strong Phase 2b data in ulcerative colitisRoche will also obtain an option to enter into a global collaboration with Pfizer on a next-generation p40/TL1A directed bispecific antibody, currently in Phase 1Under the terms of the agreement, Roche will pay a purchase price of US$ 7.1 billion upfront and a near-term milestone payment...
Source: Roche Investor Update - October 23, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
Roche will gain the rights to develop, manufacture and commercialise RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseasesRVT-3101 is a Phase 3-ready antibody with first-in-class and best-in-disease potential, a novel mode of action and strong Phase 2b data in ulcerative colitisRoche will also obtain an option to enter into a global collaboration with Pfizer on a next-generation p40/TL1A directed bispecific antibody, currently in Phase 1Under the terms of the agreement, Roche will pay a purchase price of US$ 7.1 billion upfront and a near-term milestone payment...
Source: Roche Media News - October 23, 2023 Category: Pharmaceuticals Source Type: news
Pete Davidson ’s Barbie parody completes his Pete Davidson trilogy
This week on Saturday Night Live, Pete Davidson came full circle. Just two years after departing the sketch series, Davidson returned to host the series and took the opportunity to look inward. It’s a bit of a trend for the actor, though this time the therapeutic comedy came in the form of Pete…#saturdaynightlive #petedavidson #ryangoslings #snl #crohn #arianagrande #katebeckinsale #kimkardashian #kingofstatenisland #peacocksbupkis (Source: Reuters: Health)
Source: Reuters: Health - October 15, 2023 Category: Consumer Health News Source Type: news
COVID Might Raise Odds for Immune Disorders Like Crohn's, Alopecia
TUESDAY, Oct. 10, 2023 -- In rare cases, some patients may develop an autoimmune disease following a bout of COVID, Korean researchers report.
Conditions such as alopecia (hair loss), psoriasis, vitiligo (white skin patches), vasculitis... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 10, 2023 Category: General Medicine Source Type: news
Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble
Teva stock yo-yoed and then tumbled Wednesday after the company announced it would partner with French pharma giant Sanofi (SNY) to develop an inflammatory bowel disease treatment. The drug belongs to the emerging TL1A class and could eventually rival experimental treatments from Roivant Sciences…#roivantsciences #pfe #merck #prometheusbio #teva #sanofi #tevapharmaceutical #crohn #prometheus #paulhudson (Source: Reuters: Health)
Source: Reuters: Health - October 4, 2023 Category: Consumer Health News Source Type: news
A 'SAD' Story: Patient Stuck With $176K Bill After Medicare Policy Switch
(MedPage Today) -- For 5 years, retiree George Beitzel went to a Sacramento-area clinic every 2 months so a nurse could give him an injection of the costly drug ustekinumab (Stelara), which his doctors prescribed for his Crohn's disease.
To have... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 14, 2023 Category: American Health Source Type: news
Inflammatory Bowel Disease Is on the Rise in Canada Inflammatory Bowel Disease Is on the Rise in Canada
The number of people in Canada with inflammatory bowel disease (Crohn ' s disease and ulcerative colitis) will rise to 470,000, or 1.1% of the population, by 2035, according to a new report.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - September 13, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Roche open to big acquisitions'if it makes scientific and financial sense '
Roche is open to making big acquisitions if they make "sense", Chief Executive Thomas Schinecker said, with the Swiss drugmaker unencumbered by its $20.7 billion deal last year to buy back its shares from Novartis. "Of course, we also look externally for opportunities," Schinecker, who became…#roche #thomasschinecker #novartis #schinecker #nzzamsonntag #roivantsciences #crohn (Source: Reuters: Health)
Source: Reuters: Health - September 9, 2023 Category: Consumer Health News Source Type: news
Higher Dietary Fiber Intake and Risk of IBD Higher Dietary Fiber Intake and Risk of IBD
This study investigated the association of dietary fiber intake from fruit, vegetable, bread, and cereal sources and incidence of IBD, Crohn ' s disease, and ulcerative colitis.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 7, 2023 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Statins linked to lower risk of colorectal cancer in patients with ulcerative colitis
Cholesterol-lowering statins might protect patients with ulcerative colitis from developing and dying from colorectal cancer. Statin treatment was also associated with a lower risk of death regardless of cause in patients with ulcerative colitis or Crohn's disease. This is according to a study by researchers at Karolinska Institutet in Sweden published in eClinicalMedicine. (Source: World Pharma News)
Source: World Pharma News - September 1, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Tips for Everyday Challenges of Crohn ’s
Dealing with Crohn’s symptoms? Learn the tools that can help you live well while coping with your condition. (Source: WebMD Health)
Source: WebMD Health - August 28, 2023 Category: Consumer Health News Source Type: news
Novartis' knockoff of Biogen's Tysabri is first MS biosim in US
Two months after a federal court in Delaware rejected Biogen’s patent infringement c | The FDA has endorsed Novartis' Tyruco as the first U.S. biosimilar to treat multiple sclerosis. The copycat will compete with Biogen's Tysabri, covering all of the original drug's indications for relapsing MS in…#delaware #biogen #fda #novartis #tysabri #crohn (Source: Reuters: Health)
Source: Reuters: Health - August 27, 2023 Category: Consumer Health News Source Type: news
